brukinsa
beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastische mittel - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).
cosopt sine 20 mg/ml + 5 mg/ml augentropfen, lösung im einzeldosisbehältnis
santen oy - dorzolamid hydrochlorid; timololmaleat - timolol, kombinationen
cosopt-s 20 mg/ml + 5mg/ml augentropfen im einzeldosisbehältnis
santen oy (3332582) - dorzolamidhydrochlorid; timololmaleat - augentropfen - teil 1 - augentropfen; dorzolamidhydrochlorid (26539) 22,26 milligramm; timololmaleat (12113) 6,83 milligramm
cosduo 20 mg/ml + 5 mg/ml, augentropfen, lösung
santen oy (3332582) - dorzolamidhydrochlorid; timololmaleat - augentropfen, lösung - teil 1 - augentropfen, lösung; dorzolamidhydrochlorid (26539) 22,26 milligramm; timololmaleat (12113) 6,83 milligramm
cosopt unit dose 20 mg/ml - 5 mg/ml augentropfen, lösung
santen - dorzolamide hydrochloride; timolol maleate - augentropfen, lösung - 20 mg/ml - 5 mg/ml - dorzolamide hydrochloride 22.23 mg/ml; timolol maleate 6.83 mg/ml - timolol, combinations